Octanate (Human Coagulation Factor Viii)

Human coagulation factor VIII supplied by Octanate binds to von Willebrand factor and participates in the intrinsic coagulation cascade. By restoring factor VIII activity, it enables activation of factor X, leading to thrombin generation and formation of a stable fibrin clot.

The dose of Octanate is individualized. A qualified prescriber determines the amount and frequency based on the patient’s weight, severity of deficiency, type of bleed, and clinical response. Dosing instructions are provided on the prescription label.

The safety of Octanate in pregnancy and lactation has not been fully established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order Octanate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Octanate is a plasma‑derived, high‑purity factor VIII concentrate. Compared with recombinant products, it contains a full complement of von Willebrand factor, which may influence pharmacokinetics and inhibitor risk. Choice of product depends on clinical factors, patient history and physician preference.

Octanate must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If temperature excursions occur, follow the manufacturer’s stability guidelines before use.

Octanate is supplied as a sterile solution for injection and is administered intravenously. The infusion rate and volume are determined by the prescriber, and the product should be infused using aseptic technique in a clinical setting.

The most serious risks include the development of inhibitory antibodies (inhibitors) that neutralize factor VIII activity, severe allergic or anaphylactic reactions, and rare thromboembolic events. Patients should be monitored closely for these complications.

Octanate should not be used in individuals with known hypersensitivity to human factor VIII products or any of the excipients. It is also contraindicated in patients with a history of severe allergic reactions to plasma‑derived clotting factors.